Welcome to our dedicated page for PFIZER SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PFIZER's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PFIZER's regulatory disclosures and financial reporting.
de Germay Alexandre reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Alexandre de Germay received a grant of 194,883 stock appreciation rights on Pfizer common stock. These rights were awarded at no purchase price and are classified as a derivative security. According to the terms, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On February 27, 2026, 655 shares of Pfizer common stock at $27.65 per share were withheld to cover tax obligations upon the vesting of restricted stock units, leaving her with 12,041 directly owned shares.
Pfizer Executive Vice President Payal Sahni reported transactions tied to stock appreciation rights. She exercised stock appreciation rights for 56,888 shares of common stock on February 25, 2026, at a stated exercise price of $33.82 per share, increasing her direct holdings.
To cover related tax obligations and exercise costs, 1,083 shares at $27.09 per share and 54,066 shares at $26.92 per share were withheld, classified as tax-withholding dispositions rather than open-market sales. After these transactions, she directly owned 27,667 Pfizer common shares and indirectly held 14,630 shares through a Rule 16b-3 plan.
Pfizer Inc. Executive Vice President Douglas M. Lankler settled stock-based compensation tied to stock appreciation rights on February 25, 2026. He exercised 122,907 stock appreciation rights, receiving the same number of Pfizer common shares at a reference price of $33.82 per share.
To cover related tax obligations and exercise price, 2,198 shares were withheld at $27.09 per share and 116,811 shares were withheld at $26.92 per share. Following these transactions, he held 163,177 shares of Pfizer common stock directly and 2,083 shares indirectly through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. D'Amico reported transactions tied to stock appreciation rights (SARs). On earn-out of these SARs, she acquired 17,558 shares of Pfizer common stock through an exercise or conversion at a reference price of $33.82 per share. In connection with the earn-out, 361 shares at $27.09 per share and 16,687 shares at $26.92 per share were withheld to cover tax obligations and the exercise price. After these tax-withholding dispositions, she directly owned 12,696 shares of Pfizer common stock. These moves reflect equity compensation settlement rather than open-market buying or selling.
Pfizer Inc. Chairman & CEO Albert Bourla reported multiple equity transactions involving stock appreciation rights and common shares. On February 25, 2026, he exercised 491,626 stock appreciation rights, which were settled in an equal number of Pfizer common shares at $33.82 per share.
According to the footnotes, this earn-out included dividend equivalents and used a 20-day average of Pfizer’s closing prices to determine settlement. To cover the exercise price and related tax obligations, 467,241 and 8,303 common shares were withheld at prices of $26.92 and $27.09 per share, categorized as tax-withholding dispositions rather than open-market sales.
After these transactions, Bourla directly owned 388,671 Pfizer common shares and indirectly held 6,003 additional shares through a Rule 16b-3 plan. The filing reflects an exercise and settlement of incentive awards with associated share withholding, rather than discretionary market trading.
Pfizer Inc executive Lidia Fonseca reported derivative and related share transactions tied to stock appreciation rights (SARs). On February 25, 2026, she exercised 56,888 SARs, receiving 56,888 shares of Pfizer common stock at an exercise price of $33.82 per share.
To cover taxes and exercise costs from this earn-out, 1,058 shares and 54,066 shares of common stock were withheld in tax-withholding dispositions at prices of $27.09 and $26.92 per share, respectively. After these transactions, her directly owned Pfizer common stock position was 46,455 shares, and the exercised SARs balance was reduced to zero. Footnotes specify these events arise from the earn-out and settlement terms of the SARs, which use a 20-day average closing price of Pfizer common stock.
Pfizer Inc. Executive Vice President Michael McDermott reported several equity-related transactions involving Pfizer common stock and stock appreciation rights. On February 25, 2026, he exercised 37,925 stock appreciation rights, which were settled in Pfizer common stock as part of an earn-out of these awards, including dividend equivalents. This exercise generated 37,925 common shares at a reference price of $33.82 per share, increasing his direct common stock holdings.
In connection with this earn-out and related restricted stock unit vesting, Pfizer withheld shares to cover tax obligations and exercise price. These withholding dispositions of common stock totaled 3,503 shares on February 26, 2026 at $27.10, plus 679 shares and 36,044 shares on February 25, 2026 at prices of $27.09 and $26.92 per share, respectively. After these transactions, McDermott directly held 74,308 Pfizer common shares, with the derivative stock appreciation rights position reported as fully settled.
Pfizer Inc. President of R&D Christoffel Boshoff reported equity award activity involving Pfizer common stock. On February 25, 2026, he acquired 13,383 shares at $0.0000 per share as the earn-out of performance share awards, including dividend equivalents, increasing his direct holdings to 168,212 shares.
On the same date, 6,833 shares were disposed of at $27.09 per share to cover tax obligations related to this earn-out, a tax-withholding disposition rather than an open-market sale, leaving 161,379 shares held directly. He also indirectly holds 709 shares through a Rule 16b-3 plan.
Pfizer Inc. provides a comprehensive annual overview of its global biopharmaceutical business, strategy, risks and intellectual property. The company operates mainly through its Biopharma segment, supported by contract manufacturing (PC1), while winding down Pfizer Ignite.
Pfizer reports $25.5 billion of 2025 revenue from operations outside the U.S., representing 41% of total revenues, with China and Japan highlighted as key markets. It details major products and patent expirations through 2041, emphasizes oncology, vaccines, cardiometabolic and immunology R&D, and outlines 2026 priorities: maximizing key transactions, delivering critical R&D milestones, investing for post‑2028 growth, and scaling AI across the business.